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Background: Platelet Rich Plasma (PRP), a blood-derived product rich in growth factors, is a promising treatment
for cartilage defects but there is still a lack of clinical evidence. The aim of this study is to show, through a
randomized double blind prospective trial, the efficacy of this procedure, by comparing PRP to Hyaluronic Acid (HA)
injections for the treatment of knee chondropathy or osteoarthritis (OA).
Methods: 109 patients (55 treated with HA and 54 with PRP) were treated and evaluated at 12 months of follow-up.
The patients were enrolled according to the following inclusion criteria: age> 18 years, history of chronic (at least 4
months) pain or swelling of the knee and imaging findings of degenerative changes of the joint (Kellgren-Lawrence
Score up to 3). A cycle of 3 weekly injections was administered blindly. All patients were prospectively evaluated before
and at 2, 6, and 12 months after the treatment by: IKDC, EQ-VAS, TEGNER, and KOOS scores. Range of motion and knee
circumference changes were measured over time. Adverse events and patient satisfaction were also recorded.
Results: Only minor adverse events were detected in some patients, such as mild pain and effusion after the injections,
in particular in the PRP group, where a significantly higher post-injective pain reaction was observed (p=0.039). At the
follow-up evaluations, both groups presented a clinical improvement but the comparison between the two groups
showed a not statistically significant difference in all scores evaluated. A trend favorable for the PRP group was only
found in patients with low grade articular degeneration (Kellgren-Lawrence score up to 2).
Conclusions: Results suggest that PRP injections offer a significant clinical improvement up to one year of follow-up.
However, conversely to what was shown by the current literature, for middle-aged patients with moderate signs of OA,
PRP results were not better than those obtained with HA injections, and thus it should not be considered as first line
treatment. More promising results are shown for its use in low grade degeneration, but they still have to be confirmed.
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Every day, orthopaedic, sports medicine, and rheumato-
logic physicians face the complex issue of cartilage path-
ology. Its incidence [1-3] is rapidly increasing due to
massive involvement in sports activity by the entire
population, from the young to the middle-aged and even
elderly individuals prompted by awareness of the im-
portance of physical activity as a preventive medical ap-
proach. Despite the positive aspects of this life-style,
there are also some medical problems: in particular, car-
tilage lesions are becoming one of the most important
challenges for both basic researchers and clinicians. In
fact, cartilage has limited healing potential for several
reasons: first of all, the relative isolation from systemic
regulation caused by the lack of nerves and vessels when
compared to other tissues. Furthermore, its complex
histological structure, consisting of chondrocytes sur-
rounded by matrix made of a specialized framework of
collagen, aggrecans and fluid, determines an intrinsic
vulnerability that, starting from small and focal lesions,
can develop into an accelerated degenerative process
ending in osteoarthritis (OA), a chronic condition that is
difficult to treat by conservative means. Eventually, this
process often requires a sacrificing surgical approach
such as metal resurfacing. Several treatments, both con-
servative and surgical, have been proposed to address
cartilage pathology, but results are often only partially
satisfactory and limited over time [4-6].
Current research is investigating new methods for
stimulating repair or replacing damaged cartilage. In
particular, the most recent knowledge about tissue bio-
logy concerns a complex regulation of growth factors
(GFs) for the normal tissue structure and its reaction to
damage. The influence of GFs on cartilage repair has
been investigated in vitro and in vivo [7-10], and Platelet
Rich Plasma (PRP) is a simple, low- cost and minimally-
invasive method that provides a natural concentrate of
autologous GFs from the blood [11]. This method is
now being increasingly applied in clinical practice to
treat knee degenerative pathology, such as chondropathy
and early OA [12]. The biological rational of PRP is that
platelets contain storage pools of GFs, cytokines, chemo-
kines and many other mediators [13-17]. Several in vitro
and in vivo animal studies have showed the potential
beneficial effect of PRP in promoting cellular anabolism
and tissue regeneration [7,18].
This fascinating regenerative approach has led to
promising findings but also to some controversies in the
scientific community [12,19-22].
Despite its widespread application, there is a lack of
high level studies in the literature to demonstrate the
real efficacy of PRP. We believe that it is important to
have scientifically robust studies to clearly prove the real
potential of this biological approach in order to guide itsclinical use and avoid an indiscriminate clinical applica-
tion, and therefore a high level study was designed. Due
to similarity in the current treatment indications and the
widespread use of viscosupplementation, this was chosen
as a control group, whereas for ethical reasons a placebo
group was avoided. Viscosupplementation involves the
use of intra-articular injections of hyaluronic acid (HA),
a glycosaminoglycan that provides joint lubrication,
shock absorbency, and acts as the backbone for the pro-
teoglycans of the extracellular matrix [4]. Although
beneficial effects on pain, function and patient global
assessment have been documented, the real entity of im-
provement and which of the many available HA pro-
ducts can offer the best results is not clear [23]. Even
though scientific debate on these aspects is still ongoing,
viscosupplementation is currently a widely used treat-
ment for joint degeneration pathology, thus it was
decided that HA would have been an appropriate con-
trol group for PRP.
This study shows the design of this prospective con-
trolled double-blinded randomized trial and the preli-
minary results on the first 109 patients treated and
evaluated up to 12 months of follow-up after PRP or HA
injections.
Methods
The Hospital Ethic Committee approved the study de-
sign, and patients gave their written consent to partici-
pate in this trial.
The following diagnostic criteria for patient selection
were used: patients affected by a monolateral lesion with
a history of chronic (for at least 4 months) pain or swel-
ling of the knee and imaging findings of degenerative
changes of the joint (Kellgren Lawrence 0 to III at X-ray
evaluation or MRI findings of degenerative changes in
patients presenting with no OA X-ray findings). Exclu-
sion criteria were: age > 80 years; Kellgren-Lawrence
score > 3; systemic disorders such as diabetes, rheuma-
toid arthritis, major axial deviation (varus >5°, valgus >
5°), haematological diseases (coagulopathy), severe car-
diovascular diseases, infections, immunodepression,
patients in therapy with anticoagulants or antiaggre-
gants, use of NSAIDs in the 5 days before blood dona-
tion and patients with Hb values < 11 g/dl and platelet
values < 150,000/mm3.
Patients were prospectively evaluated basally and at 2,
6, and 12 months of follow-up using IKDC, KOOS, EQ-
VAS for general health status, and Tegner scores. Fur-
thermore, at basal evaluation and at every follow-up the
ROM and the transpatellar circumference of both the
index knee and the contralateral one were measured
to check if any changes occurred over time. Patient
satisfaction and adverse events were also reported. All
the clinical evaluations were performed by a medical
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to keep the study double blinded. At the end of the
study, the nature of the injected substance was revealed
to the patients.
A power analysis was performed for the primary end-
point of IKDC subjective score improvement at the 12-
month follow-up for PRP. From a pilot study, a standard
deviation of 15.2 points was found. With an alpha error
of 0.05, a beta error of 0.2 and a minimal clinically sig-
nificant difference of 6.7 points corresponding to 1/3 of
the documented mean improvement, the minimum sam-
ple size was 83 for each group. Considering a possible
drop out of 15%, 96 patients are required for a total of
192 patients. At present, 109 patients have reached the
12 month follow-up; among these patients, 54 were trea-
ted with 3 autologous PRP intra-articular injections, and
55 were treated with 3 HA (>1500 KDa; HyalubrixW,
Fidia, Abano Terme (PD), Italy) injections. The groups
were homogeneous for sex, age, BMI, symptoms dur-
ation and previous treatments (Table 1); therefore, a
comparative analysis to have preliminary indications
could be done.
To ensure the blinding of the patients, all of them
underwent blood harvesting to obtain autologous PRP
which was used only in half of them, according to a
randomization list (the randomization list, provided by
an independent statistician, was kept in a dedicated office
that was contacted by the physician by a phone call just
before the injective procedure for the communication of
the treatment allocation). The procedure consisted of a
150-ml venous blood sample for every knee treated.
Then, 2 centrifugations (the first at 1480 rpm for 6 mi-
nutes to separate erythrocytes, and a second at 3400 rpm
for 15 minutes to concentrate platelets) produced a unit
(20 ml) of PRP. The unit of PRP was divided into 4 small
units of 5 ml each. One unit was sent to the laboratory
for analysis of platelet concentration and for a qualityTable 1 The two treatment groups are homogeneous for
all the parameters evaluated
Comparative demographics
PRP HA
N. of patients 54 55
Age 55 58 N.S.
Sex 37 M, 17 F 31 M, 24 F N.S.
BMI 27 26 N.S.
Symptoms 64 months 63 months N.S.
Kellgren 2.2 2.1 N.S.
Prev treat 7 no 5 no N.S.
13 conservative 21 conservative
34 surgical 29 surgical
Basal IKDC 50.2 ± 15.7 47.4 ± 14.0 N.S.test, whereas 3 units were stored at −30°C. Freezing them
allows the time to proceed with the quality analysis, and
this could be considered as an advantage since it
increases the safety of the procedure, thus ensuring a
controlled not contaminated intra-articular delivery of
the product. However, it has to be underlined that this
could also be considered as a disadvantage: the alteration
of the morphology and decrease in platelet functional
properties, which includes degranulation of alpha-granules,
after storing platelets in freezing conditions, is known.
However, there are no data on the effect of freezing on the
clinical results of platelet injections, and freeze-thawing is
even one of the methods used for releasing intracellular
GFs. Having freshly-harvested PRP might preserve all the
platelet functions better, but currently the data are still
controversial and it is uncertain whether freeze-thawing
adversely affects their properties to the point of impairing
their clinical efficacy.
One week after blood harvesting the injection cycle
was started, with 3 weekly injections of PRP or HA. At
the time of injection the syringe was appropriately co-
vered to prevent patients from discovering the substance
they were receiving. In the case of PRP administration,
the total number of platelets per milliliter in the PRP
represented a mean increase of 5 times compared with
whole blood values. In the platelet concentrate the pre-
sence of leukocytes was also observed, with a concentra-
tion of 1.2 times with respect to the normal blood value.
After the injection, patients were sent home with
instructions to restrict the use of the leg for at least 24
hours and to use cold therapy/ice on the affected area to
relieve pain. During this period, the use of non-steroidal
medication was forbidden. During the treatment period,
rest or mild activities (such as using an exercise bike or
mild exercise in a pool) were permitted, and subse-
quently a gradual resumption of normal sport or recrea-
tional activities was allowed, as tolerated.
Statistical analysis
All continuous data were expressed in terms of the
mean and the standard deviation of the mean. One Way
ANOVA was performed to assess differences among
groups when the Levene test for homogeneity of va-
riances was not significant (p<0.05); otherwise, the Mann
Whitney test (2 groups) or the Kruskal Wallis test (more
than 2 groups) were used. The Least Significant Differ-
ence test was performed as a post-hoc pair-wise analysis
of the Kruskal Wallis test. The generalized linear model
for repeated measures with Sidak correction for multiple
comparisons was performed to test differences of the
scores at different follow-up times. The non-parametric
Pearson’s Chi square test evaluated by Exact methods
was performed to investigate the relationships between
grouping variables. For all tests, p<0.05 was considered
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the Statistical Package for the Social Sciences (SPSS)
software version 15.0 (SPSS Inc., Chicago, USA).
Results
No major complications related to the injections were
observed during the treatment and follow-up period.
When comparing the two treatments, a significantly
higher post-injective pain reaction was observed in the
PRP group (p=0.039) (Table 2). However, this reaction
was self-limiting within a few days and did not com-
promise the overall outcome.
In fact, preliminary analysis revealed a statistically sig-
nificant improvement of all clinical scores from basal
evaluation to the 2-, 6-, and 12-month follow-ups in
both treatment groups. However, no differences could
be detected between groups in the clinical scores eva-
luated. ROM and knee circumference measurements
were also comparable at the different follow-up times. In
particular, in the PRP group the IKDC subjective score
increased from 50.2 ± 15.7 at the basal evaluation to
62.8 ± 17.6 at 2 months, 64.3 ±16.4 at 6 months, and
64.9 ± 16.8 at 12 months. In the HA group the IKDC
score increased from 47.4 ± 15.7 at the basal evaluation
to 61.4 ± 16.2 at 2 months, 61.0 ± 18.2 at 6 months, and
61.7 ± 19.0 at 12 months (Figures 1 and 2). The EQ-
VAS presented the same trend with improvements in
both groups but without any inter-group difference. The
activity level, evaluated by the Tegner score, also showed
a similar improvement for the PRP group (from basal
2.9 ±1.4 to 3.8 ± 1.3 at 12 months of follow-up) and HA
group (from basal 2.6 ± 1.2 to 3.4 ± 1.6 at 12 months of
follow-up). Finally, similar results were documented
using the KOOS score, in all sub-categories: detailed
data are shown in Table 3.
Interestingly, despite the similar general findings, fur-
ther analysis revealed slightly different results in patients
affected by different degrees of cartilage degeneration. In
fact, whereas PRP and HA could provide the same out-
come in knees with Kellgren Lawrence III level, less
degenerated joints showed a different trend, with a ten-
dency toward better results in the PRP group at 6 and 12
months of follow-up, albeit without reaching statistical
significance (p=0.08 and p=0.07, respectively) (Figure 3).Table 2 The PRP group showed a significantly higher
post injective pain reaction (p=0.039)
Level of pain and swelling: comparison
Pain Swelling
(n. of days x level 1–10) (n. of days x level 1–10)
PRP HA PRP HA
16.7 9.2 10.3 7.2
PRP > HA PRP = HAThree failures occurred, all in the HA group: in two
cases with suspected intolerance to some components of
HA, and so the injective treatment was stopped after the
first administration. In the third case the patient was still
complaining of intense pain and functional deficit and
sought other treatment in another medical center.
Discussion
Despite its wide clinical application, only a few reports
have documented results for PRP in the treatment of
knee degenerative lesions in the literature [24-34].
In 2008, Sanchez et al. published a retrospective obser-
vational study involving 60 patients [25], 30 treated with
knee intra-articular injections of PRGF and 30 with injec-
tions of HA. Patients from both groups underwent 3
weekly injections and were evaluated basally and at 5
weeks of follow-up using the WOMAC score. Results
were encouraging, even though the short follow-up is a
weak point of the study. In 2010, Sampson et al. published
a study [26] on 14 patients with clinical and radiographic
signs of OA and previous unsuccessful conservative ma-
nagement (12 men and 2 women), who received 3 PRP
injections 1 month apart. Evaluation was carried out up to
52 weeks using the “Brittberg-Peterson Visual Analog
Pain, Activities and expectation Score”, VAS for pain, and
KOOS Score: the authors found a statistically significant
improvement in the scores examined, with a reduction in
pain both at rest and during physical activity and, at 1 year
of follow-up, 8 patients were still completely satisfied with
the treatment received. In the same year, Wang-Saegusa
et al. [27] published a prospective study on 261 patients
with uni- or bilateral knee OA, symptomatic for more
than 3 months. Patients received 3 injections 2 weeks
apart, and clinical evaluation was conducted at 6 months
using the WOMAC score, VAS, Lequesne Index and SF-
36. Statistical analysis revealed significant results with an
improvement in all the scores adopted. Despite the high
number of patients evaluated, the absence of a control
group is a limiting factor in the conclusions of this study.
Napolitano et al. [28] treated 27 patients, either affected
by simple chondropathy or initial OA, with 3 injections of
5 ml PRP performed one week apart from each other, and
evaluated them up to 6 months with NRS scale for pain
and WOMAC score. Significant results were obtained
after treatment without occurrence of adverse events. The
group led by Gobbi [29] published a preliminary report on
a group of 50 active patients treated with 2 PRP injections
one month apart, showing good results at up to 1 year of
follow-up both in patients who had or had not undergone
previous operative intervention for cartilage lesions. A
study by Spakova et al. [30] compared the efficacy of PRP
versus viscosupplementation on a cohort of 120 patients
divided into two treatment groups and evaluated through
the WOMAC score and a pain numeric rating scale. At 3
Figure 1 IKDC subjective score in both PRP and HA treatment groups before and at 2, 6, and 12 months after treatment. No statistical
inter-group difference was observed.
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was observed in both groups with statistically superior
results in PRP group.
The present authors previously performed studies to
evaluate this clinical application of PRP, and recorded
safety and interesting findings [31-34]: the first one was a
prospective study published in 2009 [31] on 91 patients
(for a total of 115 knees) treated with three injections of
PRP (1 every 3 weeks). Patients underwent clinical eva-
luation at basal level and at 2, 6, and 12 months of follow-
up. Eighty percent of the patients treated expressed satis-
faction with the treatment received. The clinical outcome
revealed a statistically relevant improvement in all the
variables considered just 2 months after the end ofFigure 2 IKDC subjective results obtained with PRP and HA treatmen
Lawrence grade 0-II lesions and patients presenting grade III level oftreatment. These results were later confirmed at 6 months
of follow-up, whereas a tendency to worsen was reported
after 6 to 12 months of follow-up. Some influencing fac-
tors were detected: in particular it was observed that
young male patients were the best responding group, es-
pecially in case of simple chondropathy without signs of
OA. A later study [32] evaluating the same patients at 24
months of follow-up confirmed this trend with a further
decrease in the clinical outcome, thus concluding that
intra-articular therapy with PRP is time dependent with
an average duration of 9 months and better and longer
lasting results are achieved in younger patients with lower
levels of joint degeneration. In another multi-center study
[33], the clinical effectiveness of PRP was compared to lowts in two patient subgroups: patients affected by Kellgren
knee degeneration.
Table 3 KOOS score in all five subcategories before and at 2, 6, and 12 months after the treatment
KOOS score trend in both treatment groups
KOOS BASAL 2 MONTHS 6 MONTHS 12 MONTHS
Symptoms PRP 64.0+−17.9 71.9+−17.0 73.0+−18.3 71.3+−17.9
HA 67.8+−15.7 71.6+−16.3 74.3+−16.0 74.2+−17.5
Pain PRP 65.4+−17.7 73.1+−21.5 74.2+−19.6 74.0+−19.4
HA 63.1+−17.4 71.1+−18.6 73.2+−18.1 74.0+−19.4
Activity of daily life PRP 69.9 +− 20.0 81.2+−17.9 79.1+−19.0 77.9+−20.6
HA 67.8+−21.0 78.2+−17.4 77.3+−18.6 77.3+−19.8
Sport PRP 37.6+−24.7 48.8+−25.9 48.7+−29.5 47.4+−28.2
HA 34.2+−23.9 45.0+−24.1 44.7+−27.8 46.6+−27.9
Quality of life PRP 34.9+−18.8 48.3+−22.6 48.0+−23.1 50.5+−22.6
HA 33.6+−18.0 45.5+−23.9 48.5+−24.7 49.2+−26.0
No statistical difference was reported in any subcategory between groups.
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HA (HWHA). Three homogeneous groups of patients
were respectively treated with 3 injections of PRP, LWHA,
or HWHA. The results highlighted a better performance
for PRP group at 6 months of follow-up. In particular, sub-
group analysis (chondropathy vs early vs severe OA)
revealed that in the chondropathy group PRP gave mark-
edly better results than HA at 6 months of follow-up,
whereas in the early OA group the gap in favor of PRP
was reduced and in the severe OA subgroup no difference
in clinical outcome was observed between treatments.Figure 3 IKDC subjective improvement from basal level to 2, 6, and 1
in low grade cartilage degenerative pathology. A tendency towards be
12 months: p = 0.08 and p = 0.07, respectively.Furthermore, patients under 50 years old have a greater
chance to benefit from this biological approach with this
GFs supplementation. Finally, the present authors recently
published a comparative study between PRP with or with-
out leukocytes used to treat 144 patients affected by knee
cartilage pathology, and showed comparable positive cli-
nical effects with both treatments, with PRP-leukocyte
group suffering from more swelling and pain reaction after
the injections [34].
Despite the increasing number of reports, there is a
lack of high level studies: only one randomized clinical2 months of follow-up after treatment with PRP or HA injections
tter results for PRP in this patient category is observed at both 6 and
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study led by Sanchez who compared at short-term follow-
up PRGF (a single spinning procedure giving a leukocyte
free PRP with a low platelet concentration) with HA admi-
nistered on a weekly basis for the treatment of sympto-
matic knee OA. With these treatments, adverse events
were mild and evenly distributed between the PRP and
HA groups. The rate of response to PRGF was higher in
all outcome measures, although no significant differences
were found; however, compared with the rate of response
to HA, the rate of response to PRGF (primary outcome
measure) was 14.1 percentage points significantly higher.
In the present authors’ studies a different platelet con-
centrate was used, obtained through a double-spinning
procedure which provides many platelets but also leuko-
cytes. Cellularity is one of the most debated aspects when
evaluating PRP properties and the results obtained with its
application. In fact, not only platelets but also leukocytes,
monocytes, macrophages, and mast cells are contained in
many platelet concentrates. Some authors define PRP as
only platelets and attribute better results to leucocyte de-
pletion, because of the deleterious effects of proteases and
reactive oxygen released from white cells; others consider
them as a source of important cytokines and enzymes,
that may be important also for the prevention of infec-
tions, and report that PRP significantly inhibits the growth
of Staphylococcus Aureus and Escherichia Coli [7].
This is the first double-blind randomized clinical trial
available in the literature on this kind of double-spinning
high concentrate leukocyte PRP, and more in general it is
also the first randomized trial with such a high number of
patients evaluated at 12 months of follow-up. For these rea-
sons, despite being preliminary with respect to the object-
ive of the entire study, the present results on the evaluated
cohorts of patients are already significant representing up
to now one of the highest available evidence on PRP use
for knee degenerative pathology, and already give us some
indications on the potential of this biological approach.
The analysis of the results obtained with this rando-
mized trial has already underlined important aspects.
The safety and the significant clinical improvement of
this procedure were confirmed. A higher pain reaction
after PRP injection was found, probably due to the
leukocyte content of our platelet concentrate, but with-
out jeopardizing clinical results up to 1 year follow-up.
Conversely to what was shown by the current literature
of comparative studies [25,30,33,35], PRP did not offer
better results compared to HA in this series. However, it
has to be emphasized that the average age of the en-
rolled patients was higher than those of other studies
and the present authors previously observed a worse
outcome for older patients treated with PRP [31,32], and
a sub-analysis of different patient categories showed
some interesting findings. In fact, a tendency towardsbetter results at both 6 and 12 months of follow-up in
favor of PRP treatment was seen for the less degenerated
cases. It is important to consider that this is a subanaly-
sis, and therefore the sample size is smaller and less sup-
portive of the preliminary results found. The completion
of the entire planned 192 patient evaluation will confirm
whether this trend will reach a statistical and clinical sig-
nificance, thus demonstrating a clear indication for this
biological treatment approach, as well as the potential of
the double spinning high concentrate leukocyte PRP
with respect to the single spinning low concentrate
leukocyte free PRP that recently showed better results
with respect to HA [35].
For now, the results of this trial suggest a possible effect
of this platelet concentrate on the treatment of knee de-
generative pathology, with a clinical subjective improve-
ment but not significantly better results with respect to
HA; a tendency towards better improvement only in
patients affected by earlier degrees of knee degeneration
was observed, thus suggesting that the clinical application
of PRP should be mainly restricted to this patient sub-
group, whereas the indication of this treatment for high
grade degeneration is lower. Due to the not significantly
better results with respect to HA, PRP cannot be consid-
ered as the first line of treatment for knee OA and should
be therefore restricted to patients who do not benefit from
other conservative or injective treatments such as HA or,
if used as first line treatment, it should be mainly targeted
to patients affected only by early degrees of knee cartilage
degeneration.
Conclusion
PRP is a new treatment for knee degenerative pathologies
and an increasing number of studies show promising
results. However, despite its wide application in the clinical
practice and the positive findings reported, there is a lack
of scientific background to guide the clinical application of
PRP. To avoid indiscriminate and inappropriate use of
PRP, it is important to determine the type of patients who
will not benefit from this treatment, and therefore the
authors designed a high level study to understand clearly
the indication of this treatment. The present results sug-
gest, conversely to what was shown by the current litera-
ture, that for middle-aged patients with moderate signs of
OA, PRP did not offer better results compared to HA, and
thus it should not be considered as first line treatment.
More promising results are shown for its use in less dege-
nerated cases, but they still need to be confirmed.
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